Literature DB >> 26021325

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.

Amarjit S Chaudhry1, Bhagwat Prasad1, Yoshiyuki Shirasaka1, Alison Fohner1, David Finkelstein1, Yiping Fan1, Shuoguo Wang1, Gang Wu1, Eleni Aklillu1, Sarah C Sim1, Kenneth E Thummel1, Erin G Schuetz2.   

Abstract

CYP2C19 rs12769205 alters an intron 2 branch point adenine leading to an alternative mRNA in human liver with complete inclusion of intron 2 (exon 2B). rs12769205 changes the mRNA reading frame, introduces 87 amino acids, and leads to a premature stop codon. The 1000 Genomes project (http://browser.1000genomes.org/index.html) indicated rs12769205 is in linkage disequilibrium with rs4244285 on CYP2C19*2, but found alone on CYP2C19*35 in Blacks. Minigenes containing rs12769205 transfected into HepG2 cells demonstrated this single nucleotide polymorphism (SNP) alone leads to exon 2B and decreases CYP2C19 canonical mRNA. A residual amount of CYP2C19 protein was detectable by quantitative proteomics with tandem mass spectrometry in CYP2C19*2/*2 and *1/*35 liver microsomes with an exon 2 probe. However, an exon 4 probe, downstream from rs12769205, but upstream of rs4244285, failed to detect CYP2C19 protein in livers homozygous for rs12769205, demonstrating rs12769205 alone can lead to complete loss of CYP2C19 protein. CYP2C19 genotypes and mephenytoin phenotype were compared in 104 Ethiopians. Poor metabolism of mephenytoin was seen in persons homozygous for both rs12769205 and rs4244285 (CYP2C19*2/*2), but with little effect on mephenytoin disposition of CYP2C19*1/*2, CYP2C19*1/*3, or CYP2C19*1/*35 heterozygous alleles. Extended haplotype homozygosity tests of the HapMap Yorubans (YRI) showed both haplotypes carrying rs12769205 (CYP2C19*35 and CYP2C19*2) are under significant natural selection, with CYP2C19*35 having a higher relative extended haplotype homozygosity score. The phylogenetic tree of the YRI CYP2C19 haplotypes revealed rs12769205 arose first on CYP2C19*35 and that rs4244285 was added later, creating CYP2C19*2. In conclusion, rs12769205 is the ancestral polymorphism leading to aberrant splicing of CYP2C19*35 and CYP2C19*2 alleles in liver.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26021325      PMCID: PMC4518065          DOI: 10.1124/dmd.115.064428

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  38 in total

1.  Detecting recent positive selection in the human genome from haplotype structure.

Authors:  Pardis C Sabeti; David E Reich; John M Higgins; Haninah Z P Levine; Daniel J Richter; Stephen F Schaffner; Stacey B Gabriel; Jill V Platko; Nick J Patterson; Gavin J McDonald; Hans C Ackerman; Sarah J Campbell; David Altshuler; Richard Cooper; Dominic Kwiatkowski; Ryk Ward; Eric S Lander
Journal:  Nature       Date:  2002-10-09       Impact factor: 49.962

2.  Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing.

Authors:  Gopal Singh; Thomas A Cooper
Journal:  Biotechniques       Date:  2006-08       Impact factor: 1.993

3.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

4.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

Review 5.  Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Authors:  J K Hicks; J J Swen; C F Thorn; K Sangkuhl; E D Kharasch; V L Ellingrod; T C Skaar; D J Müller; A Gaedigk; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2013-01-16       Impact factor: 6.875

6.  Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.

Authors:  Yoshiyuki Shirasaka; Jennifer E Sager; Justin D Lutz; Connie Davis; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

7.  Exome sequencing identifies a branch point variant in Aarskog-Scott syndrome.

Authors:  Emmelien Aten; Yu Sun; Rowida Almomani; Gijs W E Santen; Tobias Messemaker; Saskia M Maas; Martijn H Breuning; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2012-12-20       Impact factor: 4.878

Review 8.  Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.

Authors:  Takeshi Hirota; Shunsuke Eguchi; Ichiro Ieiri
Journal:  Drug Metab Pharmacokinet       Date:  2012-11-20       Impact factor: 3.614

9.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

10.  Sequence features responsible for intron retention in human.

Authors:  Noboru Jo Sakabe; Sandro José de Souza
Journal:  BMC Genomics       Date:  2007-02-26       Impact factor: 3.969

View more
  11 in total

Review 1.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

2.  Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.

Authors:  Helmi Ammar; Zohra Chadli; Ahmed Mhalla; Sabria Khouadja; Ibtissem Hannachi; Mohammed Alshaikheid; Ahlem Slama; Nadia Ben Fredj; Najeh Ben Fadhel; Haifa Ben Romdhane; Amel Chaabane; Naceur A Boughattas; Lotfi Gaha; Lazhar Zarrouk; Karim Aouam
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

3.  Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data.

Authors:  Geik Yong Ang; Choo Yee Yu; Vinothini Subramaniam; Mohd Ikhmal Hanif Abdul Khalid; Tuan Azlin Tuan Abdu Aziz; Richard Johari James; Aminuddin Ahmad; Thuhairah Abdul Rahman; Fadzilah Mohd Nor; Adzrool Idzwan Ismail; Kamarudzaman Md Isa; Hood Salleh; Lay Kek Teh; Mohd Zaki Salleh
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

4.  Idiopathic male infertility in the Han population in China is affected by polymorphism in the VDAC2 gene.

Authors:  Lianjun Pan; Daoxian Qiu; Jingyun Li; Jun Li; Pu Xu; Dan Zhao; Jiehua Ma
Journal:  Oncotarget       Date:  2016-12-13

5.  Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole.

Authors:  Lorena Díaz-Ordóñez; Diana Ramírez-Montaño; Estephania Candelo; Carolina González-Restrepo; Sebastián Silva-Peña; Carlos Arturo Rojas; Mario Sepulveda Copete; Hector Raul Echavarria; Harry Pachajoa
Journal:  Pharmgenomics Pers Med       Date:  2021-04-29

6.  A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy.

Authors:  Mariana Angulo-Aguado; Karen Panche; Caroll Andrea Tamayo-Agudelo; Daniel-Armando Ruiz-Torres; Santiago Sambracos-Parrado; Maria Jose Niño-Orrego; Nathaly Páez; Laura B Piñeros-Hernandez; Luisa-Fernanda Castillo-León; Juan Mauricio Pardo-Oviedo; Katherine Parra Abaunza; Paul Laissue; Nora Contreras; Carlos Alberto Calderón-Ospina; Dora Janeth Fonseca-Mendoza
Journal:  J Pers Med       Date:  2021-05-12

7.  Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.

Authors:  Joel A Morales-Rosado; Kashish Goel; Lingxin Zhang; Axel Åkerblom; Saurabh Baheti; John L Black; Niclas Eriksson; Lars Wallentin; Stefan James; Robert F Storey; Shaun G Goodman; Gregory D Jenkins; Bruce W Eckloff; Suzette J Bielinski; Hugues Sicotte; Stephen Johnson; Veronique L Roger; Liewei Wang; Richard Weinshilboum; Eric W Klee; Charanjit S Rihal; Naveen L Pereira
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.947

8.  The effect of CYP1A2 gene polymorphism on the metabolism of theophylline.

Authors:  Shijuan Xiong; Lingling Li
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

Review 9.  Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.

Authors:  Sherry-Ann Brown; Naveen Pereira
Journal:  J Pers Med       Date:  2018-01-30

10.  Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.

Authors:  Sumonrat Chuwongwattana; Thawinee Jantararoungtong; Santirat Prommas; Sadeep Medhasi; Apichaya Puangpetch; Chonlaphat Sukasem
Journal:  Pharmacol Res Perspect       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.